ICML 2023 | Zamtocabtagene autoleucel for the treatment of patients with R/R DLBCL
Matthew Ulrickson
• 15 Jun 2023
Matthew Ulrickson, MD, Banner MD Anderson Cancer Center, Gilbert, AZ, shares some insights into the promise of zamtocabtagene autoleucel (zamto-cel) for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Ulrickson highlights the value of this dual-targeting CAR and further comments on the high overall response rate (ORR) and favorable outcomes observed with this agent. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
